{"id":5581,"date":"2025-10-13T12:17:19","date_gmt":"2025-10-13T12:17:19","guid":{"rendered":"https:\/\/regenerated.health\/eczema-treatment\/"},"modified":"2026-03-31T12:51:23","modified_gmt":"2026-03-31T12:51:23","slug":"eczema-treatment","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/eczema-treatment\/","title":{"rendered":"Eczema Treatment: Steroids, Biologics, Natural Options"},"content":{"rendered":"\n<div class=\"at-a-glance\">\n<h2>At a Glance<\/h2>\n<ul>\n<li>Daily moisturizing is the foundation of all eczema management, regardless of severity<\/li>\n<li>Topical corticosteroids remain first-line for flares; steroid phobia causes more harm than steroids themselves<\/li>\n<li>Dupilumab (Dupixent) and JAK inhibitors have transformed treatment for moderate-to-severe eczema<\/li>\n<li>Wet wrap therapy can break severe flare cycles without increasing steroid dose<\/li>\n<li>A proactive maintenance approach (treating before flares start) outperforms reactive treatment<\/li>\n<\/ul>\n<\/div>\n\n<h2>The Treatment Ladder<\/h2>\n\n<p>Eczema (atopic dermatitis) treatment follows a stepwise approach based on severity. The critical point most patients miss: the foundation (moisturizing, trigger avoidance, and skin care routine) must be in place at every severity level. Adding medications on top of a broken skin care foundation produces poor results [1].<\/p>\n\n<h2>Step 1: Skin Care Foundation (All Patients)<\/h2>\n\n<h3>Moisturizers (Emollients)<\/h3>\n\n<p>The single most important intervention for eczema. Eczema skin has a defective skin barrier (often involving filaggrin gene mutations) that allows transepidermal water loss and allergen\/irritant penetration. Daily moisturizing restores barrier function [2].<\/p>\n\n<p>Choosing the right moisturizer:<\/p>\n<ul>\n<li><strong>Ointments (petroleum jelly, Aquaphor):<\/strong> Most occlusive, best barrier repair. Greasy feel limits daytime use for some patients. Best applied at night.<\/li>\n<li><strong>Creams (CeraVe, Vanicream, Cetaphil):<\/strong> Good balance of efficacy and cosmetic acceptability. Look for ceramides, which directly restore the lipid bilayer.<\/li>\n<li><strong>Lotions:<\/strong> Least occlusive, evaporate quickly. Insufficient for active eczema. Fine for very mild or inactive disease.<\/li>\n<\/ul>\n\n<p>Application protocol: apply within 3 minutes of bathing (on damp skin) to lock in moisture. Full body, at least once daily. Twice daily on active areas. Use liberally: a child needs 250 g\/week, an adult needs 500 g\/week for full coverage.<\/p>\n\n<h3>Bathing Practices<\/h3>\n<ul>\n<li>Lukewarm water (not hot), 5-10 minutes<\/li>\n<li>Fragrance-free, soap-free cleanser only on dirty areas (groin, axillae, feet). Avoid cleansing eczema-prone areas unless actually soiled.<\/li>\n<li>Pat dry gently, do not rub<\/li>\n<li>Apply moisturizer immediately<\/li>\n<li>Bleach baths (quarter cup regular bleach in a full bathtub, 2x\/week) reduce Staphylococcus aureus colonization, which triggers flares in 90% of eczema patients [3]<\/li>\n<\/ul>\n\n<h3>Trigger Avoidance<\/h3>\n<ul>\n<li>Fragrance-free everything: detergent, soap, lotion, dryer sheets<\/li>\n<li>Cotton or bamboo clothing (avoid wool and synthetic fabrics against skin)<\/li>\n<li>Temperature regulation: overheating and sweating trigger flares<\/li>\n<li>Dust mite reduction if sensitized: encased pillows and mattress, hot-water washing of bedding<\/li>\n<\/ul>\n\n<h2>Step 2: Topical Anti-Inflammatory Treatment<\/h2>\n\n<h3>Topical Corticosteroids (TCS)<\/h3>\n\n<p>The first-line anti-inflammatory for eczema flares. Available in 7 potency classes (Class I strongest, Class VII weakest in the US system). Choosing the right potency for the right location is the key skill [4]:<\/p>\n\n<table>\n<thead>\n<tr><th>Body Area<\/th><th>Recommended Potency<\/th><th>Examples<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Face, eyelids, genitals<\/td><td>Low (Class VI-VII)<\/td><td>Hydrocortisone 1-2.5%, desonide 0.05%<\/td><\/tr>\n<tr><td>Skin folds (axillae, groin)<\/td><td>Low to medium<\/td><td>Desonide, triamcinolone 0.025%<\/td><\/tr>\n<tr><td>Trunk, arms, legs<\/td><td>Medium (Class III-V)<\/td><td>Triamcinolone 0.1%, mometasone 0.1%<\/td><\/tr>\n<tr><td>Hands, feet, thick plaques<\/td><td>High to super-high (Class I-II)<\/td><td>Clobetasol 0.05%, betamethasone dipropionate 0.05%<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<p>Addressing steroid phobia: topical corticosteroid side effects (skin thinning, stretch marks, telangiectasia) occur with prolonged continuous use of inappropriate potency on thin-skinned areas. Used correctly (right potency, right location, 2-4 week courses with maintenance), TCS are safe. Undertreatment from steroid fear causes more disease burden than appropriate steroid use [5].<\/p>\n\n<h3>Proactive Maintenance (&#8220;Weekend Therapy&#8221;)<\/h3>\n<p>Instead of waiting for flares and treating reactively, apply mid-potency TCS to previously affected areas 2x\/week even when the skin appears clear. This approach reduces relapse rates by 50-70% in clinical trials and is now the standard recommendation for patients with frequently relapsing eczema.<\/p>\n\n<h3>Topical Calcineurin Inhibitors (TCI)<\/h3>\n<ul>\n<li><strong>Tacrolimus 0.03% and 0.1% (Protopic):<\/strong> As effective as medium-potency TCS without atrophy risk. Ideal for face, eyelids, and genital areas for long-term use. Common side effect: burning\/stinging on application (resolves after a few days).<\/li>\n<li><strong>Pimecrolimus 1% (Elidel):<\/strong> Less potent than tacrolimus. Best for mild-to-moderate disease on sensitive areas. Good for maintenance therapy.<\/li>\n<\/ul>\n\n<h3>Topical PDE4 Inhibitor<\/h3>\n<ul>\n<li><strong>Crisaborole 2% (Eucrisa):<\/strong> A non-steroidal, non-calcineurin inhibitor option for mild-to-moderate eczema. Less effective than medium-potency TCS but offers a steroid-free option. Main side effect: application site stinging.<\/li>\n<\/ul>\n\n<h3>Topical JAK Inhibitor<\/h3>\n<ul>\n<li><strong>Ruxolitinib 1.5% cream (Opzelura):<\/strong> Approved for mild-to-moderate atopic dermatitis. Anti-itch effect is rapid (within 36 hours). Provides a new mechanism for patients who prefer non-steroidal options. Use limited to 20% BSA and 60 g per cycle due to systemic absorption concerns.<\/li>\n<\/ul>\n\n<h2>Step 3: Phototherapy<\/h2>\n\n<p>Narrowband UVB (NB-UVB) is effective for moderate-to-severe eczema that is widespread and poorly controlled with topicals alone. Treatment is 2-3 times weekly for 8-12 weeks in a light booth or with a home unit [6].<\/p>\n\n<p>Mechanism: UVB suppresses T-cell mediated skin inflammation, reduces pruritus, and improves barrier function. It is safe for long-term use and can be combined with topical therapies.<\/p>\n\n<p>Limitations: requires frequent clinic visits (or a home unit), time-consuming, and not practical for localized disease. Most effective for trunk and limb eczema.<\/p>\n\n<h2>Step 4: Systemic Therapies<\/h2>\n\n<h3>Dupilumab (Dupixent)<\/h3>\n\n<p>A monoclonal antibody blocking IL-4 and IL-13, the key type 2 inflammatory cytokines driving eczema. Approved for moderate-to-severe atopic dermatitis in adults and children aged 6 months and older [7].<\/p>\n\n<ul>\n<li>EASI-75 (75% improvement) in 44-51% of patients at 16 weeks (vs. 12-15% placebo)<\/li>\n<li>Dramatic itch reduction (average 50-60% reduction in peak pruritus score)<\/li>\n<li>Onset of itch relief within 2 weeks; skin improvement over 4-16 weeks<\/li>\n<li>Self-administered subcutaneous injection every 2 weeks<\/li>\n<li>Main side effect: conjunctivitis (10-20%), injection site reactions<\/li>\n<li>No immunosuppressive monitoring required. No increased infection risk.<\/li>\n<\/ul>\n\n<p>Dupilumab was a paradigm shift for eczema treatment. For the first time, patients with severe, refractory eczema had an effective, safe, long-term option.<\/p>\n\n<h3>JAK Inhibitors (Oral)<\/h3>\n<ul>\n<li><strong>Abrocitinib (Cibinqo):<\/strong> JAK1 inhibitor. 100-200 mg daily oral. Rapid onset (itch improvement within days). EASI-75 in 44-63%. Risk considerations: herpes zoster, acne, nausea, headache.<\/li>\n<li><strong>Upadacitinib (Rinvoq):<\/strong> JAK1 inhibitor. 15-30 mg daily oral. EASI-75 in 62-73% (highest clearance rates among current systemic options). Outperformed dupilumab in head-to-head trials for skin clearance, though safety profile is narrower.<\/li>\n<li><strong>Baricitinib (Olumiant):<\/strong> JAK1\/JAK2 inhibitor. 2-4 mg daily. Approved in Europe and some other markets for eczema. Lower efficacy than abrocitinib and upadacitinib.<\/li>\n<\/ul>\n\n<p>JAK inhibitors require monitoring: CBC, liver function, lipids, and screening for tuberculosis and hepatitis before starting. Risk of herpes zoster is elevated; vaccination before starting is recommended.<\/p>\n\n<h3>Tralokinumab (Adbry)<\/h3>\n<p>An IL-13-specific monoclonal antibody. Subcutaneous injection every 2 weeks. EASI-75 in 25-33% as monotherapy. Less effective than dupilumab in indirect comparisons but may benefit patients who do not respond to or cannot tolerate dupilumab.<\/p>\n\n<h3>Traditional Immunosuppressants<\/h3>\n<p>Used less frequently now that biologics and JAK inhibitors are available, but still relevant when access or cost is a barrier:<\/p>\n<ul>\n<li><strong>Cyclosporine:<\/strong> Rapid onset, effective. Limited to 1-2 years due to nephrotoxicity. Useful as a bridge to biologic therapy.<\/li>\n<li><strong>Methotrexate:<\/strong> Slow onset (8-12 weeks). Modest efficacy. Lower cost. Weekly dosing.<\/li>\n<li><strong>Azathioprine:<\/strong> Slow onset. Used when other options fail or are unavailable. TPMT testing required before starting.<\/li>\n<li><strong>Mycophenolate mofetil:<\/strong> Off-label. Moderately effective. Used as a steroid-sparing agent.<\/li>\n<\/ul>\n\n<h2>Managing Itch<\/h2>\n\n<p>Pruritus is the most disabling symptom of eczema and the primary driver of the itch-scratch cycle that worsens disease. Beyond anti-inflammatory treatment:<\/p>\n<ul>\n<li><strong>Keep nails short:<\/strong> Reduces scratch damage<\/li>\n<li><strong>Cold compresses:<\/strong> Immediate but temporary itch relief through TRPM8 activation<\/li>\n<li><strong>Oral antihistamines:<\/strong> Sedating antihistamines (hydroxyzine, diphenhydramine) help with nighttime itch through sedation, not direct anti-itch action. Non-sedating antihistamines (cetirizine, loratadine) are not effective for eczema itch.<\/li>\n<li><strong>Menthol-containing creams (0.5-1%):<\/strong> Topical counter-irritant that provides temporary itch relief<\/li>\n<\/ul>\n\n<h2>Wet Wrap Therapy<\/h2>\n\n<p>A highly effective technique for breaking severe flare cycles. Protocol [8]:<\/p>\n<ol>\n<li>Bathe in lukewarm water for 10 minutes<\/li>\n<li>Apply topical corticosteroid (diluted or standard potency, per provider guidance) to affected areas<\/li>\n<li>Apply a thick layer of emollient over the entire body<\/li>\n<li>Cover with a damp layer of tubular bandage or wet cotton clothing<\/li>\n<li>Cover with a dry layer on top<\/li>\n<li>Leave on for 2-4 hours (or overnight)<\/li>\n<\/ol>\n\n<p>Wet wraps increase topical medication absorption by 10x, provide physical barrier against scratching, cool the skin, and restore hydration. Typically used for 3-7 consecutive days during severe flares.<\/p>\n\n<h2>Natural and Complementary Approaches<\/h2>\n\n<ul>\n<li><strong>Sunflower seed oil:<\/strong> Contains linoleic acid, which supports skin barrier repair. Applied topically, it has shown benefit in neonatal studies. Use as a supplement to (not replacement for) standard emollients.<\/li>\n<li><strong>Coconut oil:<\/strong> Has antimicrobial properties against S. aureus. A small RCT showed improvement in SCORAD scores versus mineral oil. Safe as a supplemental emollient.<\/li>\n<li><strong>Evening primrose oil:<\/strong> Contains gamma-linolenic acid (GLA). Oral supplementation studies show mixed results. A 2013 Cochrane review found insufficient evidence to recommend.<\/li>\n<li><strong>Probiotics:<\/strong> Evidence for prevention (prenatal\/early life supplementation reduces eczema risk by 20-30%). Evidence for treatment of established eczema is weaker, with some benefit for Lactobacillus rhamnosus strains [9].<\/li>\n<li><strong>Vitamin D:<\/strong> Deficiency is common in eczema. Supplementation may reduce winter flare severity, particularly in children.<\/li>\n<\/ul>\n\n<h2>When to See a Dermatologist<\/h2>\n\n<ul>\n<li>Eczema covers more than 10% of body surface area<\/li>\n<li>Symptoms are not controlled with OTC moisturizers and low-potency steroids<\/li>\n<li>Sleep is disrupted by itch more than 2 nights per week<\/li>\n<li>Recurrent skin infections (crusting, weeping, honey-colored drainage) suggest S. aureus infection requiring antibiotics<\/li>\n<li>Eczema affects the face, hands, or genitals and topicals are not sufficient<\/li>\n<li>You want to discuss biologic or systemic therapy options<\/li>\n<\/ul>\n\n<h2>Related Reading<\/h2>\n<ul>\n<li><a href=\"\/blog\/eczema\">Eczema: The Evidence-Based Guide<\/a> (Pillar)<\/li>\n<li><a href=\"\/blog\/dyshidrotic-eczema\">Dyshidrotic Eczema: Hand and Foot Blistering Eczema Guide<\/a><\/li>\n<\/ul>\n\n<h2>References<\/h2>\n<ol>\n<li>Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. <em>J Eur Acad Dermatol Venereol<\/em>. 2018;32(5):657-682. doi:10.1111\/jdv.14891<\/li>\n<li>van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. <em>Cochrane Database Syst Rev<\/em>. 2017;2(2):CD012119. doi:10.1002\/14651858.CD012119.pub2<\/li>\n<li>Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. <em>Pediatrics<\/em>. 2009;123(5):e808-e814. doi:10.1542\/peds.2008-2217<\/li>\n<li>Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. <em>J Am Acad Dermatol<\/em>. 2014;71(1):116-132. doi:10.1016\/j.jaad.2014.03.023<\/li>\n<li>Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. <em>Br J Dermatol<\/em>. 2000;142(5):931-936. doi:10.1046\/j.1365-2133.2000.03473.x<\/li>\n<li>Garritsen FM, Brouwer MW, Limpens J, et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. <em>Br J Dermatol<\/em>. 2014;170(3):501-513. doi:10.1111\/bjd.12645<\/li>\n<li>Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. <em>N Engl J Med<\/em>. 2016;375(24):2335-2348. doi:10.1056\/NEJMoa1610020<\/li>\n<li>Nicol NH, Boguniewicz M. Wet wrap therapy in moderate to severe atopic dermatitis. <em>Immunol Allergy Clin North Am<\/em>. 2017;37(1):123-139. doi:10.1016\/j.iac.2016.08.003<\/li>\n<li>Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. <em>Allergy<\/em>. 2015;70(11):1356-1371. doi:10.1111\/all.12700<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Eczema treatment has moved far beyond steroid creams. Here&#8217;s the full treatment ladder from moisturizers to dupilumab, with realistic expectations for each.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1005],"tags":[],"class_list":["post-5581","post","type-post","status-publish","format-standard","hentry","category-autoimmune-inflammatory"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5581"}],"version-history":[{"count":1,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5581\/revisions"}],"predecessor-version":[{"id":5681,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5581\/revisions\/5681"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}